HIGHCROFT INVESTMENTS PLC
("Highcroft" or the "Company")
Director/PDMR Shareholding
The Company was notified today that, following changes to family trusts, David Kingerlee's non-beneficial holdings have reduced by 37,470 shares.
As a result of these changes the disclosable interest of David Kingerlee, a director of the Company, is 1,498,333 ordinary shares and the combined holding of the Kingerlee Concert Party is 2,126,996 ordinary shares.
For further information, contact:
Highcroft Investments PLC
Roberta Miles 01865 840023
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1
| Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | J M Kingerlee Settlement (a trust of which David Kingerlee is a trustee) | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | PCA of David Kingerlee (a director of the company) | ||||
| b) | Initial notification /Amendment | Initial | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Highcroft Investments PLC | ||||
| b) | LEI | 213800F867TBILNX3B27 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument Identification code | Ordinary Shares
00042548875 | ||||
| b) | Nature of the transaction | Change in trust arrangements | ||||
| c)
| Price(s) and volume(s) |
| ||||
| d)
| Aggregated information - Aggregated volume - Price |
37,470 nil | ||||
| e) | Date of the transaction | 8 January 2020 | ||||
| f) | Place of the transaction | XOFF | ||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.